雄激素剥夺治疗与心血管风险:GnRH拮抗剂与激动剂间无有意义差异——基于2010-2013年法国医疗保险数据的全国人群队列研究
该研究利用法国全国理赔数据库识别2010年7月1日至2011年12月31日启动ADT或行睾丸切除术的前列腺癌成年男性,随访至2013年12月31日。在35,118例新ADT使用者中,与GnRH激动剂相比,CAB与缺血事件风险升高相关(调整HR 1.6,95%CI 1.3-2.0),AA与风险降低相关(调整HR 0.6,95%CI 0.4-0.9),GnRH拮抗剂无显著关联(调整HR 1.2,95%CI 0.7-2.1)。作者认为GnRH拮抗剂与激动剂间存在临床有意义差异的概率较低。
要点
- 与GnRH激动剂相比,CAB与缺血事件风险升高相关(调整HR 1.6,95%CI 1.3-2.0)。
- 与GnRH激动剂相比,AA与缺血事件风险降低相关(调整HR 0.6,95%CI 0.4-0.9)。
- GnRH拮抗剂与缺血事件无显著关联(调整HR 1.2,95%CI 0.7-2.1)。
核心结论
- 心血管风险在不同ADT方式间似乎存在差异,但GnRH拮抗剂与激动剂比较时存在临床有意义差异的概率似乎较低。
- 在追求不损害生活质量的更佳总生存和肿瘤特异性生存的背景下,心血管疾病发病的潜在异质性在选择ADT时变得至关重要。
研究设计与样本
- 基于法国全国人群理赔报销数据库 linked to hospital discharge database 的队列研究。
- 纳入2010年7月1日至2011年12月31日启动ADT(GnRH激动剂或拮抗剂、抗雄激素、联合雄激素阻断)或行睾丸切除术的前列腺癌成年男性,随访至2013年12月31日。
- 主要分析采用on-treatment方法,在首次治疗调整时删失所有患者,使用Cox回归估计缺血事件住院的风险比,调整年龄和基线合并症,并将死亡作为竞争风险。
主要发现
- 在35,118例新ADT使用者中,71%接受GnRH激动剂(参照组),12%接受CAB,13%接受AA,3.6%接受GnRH拮抗剂,0.6%行睾丸切除术。
- 与GnRH激动剂相比,CAB与缺血事件风险升高相关(调整HR 1.6,95%CI 1.3-2.0)。
- 与GnRH激动剂相比,AA与缺血事件风险降低相关(调整HR 0.6,95%CI 0.4-0.9)。
- 与GnRH激动剂相比,GnRH拮抗剂与缺血事件无显著关联(调整HR 1.2,95%CI 0.7-2.1)。
临床怎么用
- 作者认为,在选择ADT时,心血管疾病发病的潜在异质性至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies suggested that androgen deprivation therapy (ADT) is associated with an increased cardiovascular (CV) risk. They all compared ADT-treated cancer patients to non-treated patients or non-cancer subjects. Our aim was to evaluate whether CV risk differs by type of ADT. METHODS: Through nationwide population-based claims reimbursement database linked to hospital discharge database, we identified adult men with prostate cancer who initiated ADT (gonadotrophin releasing hormone [GnRH] agonist or antagonist, antiandrogen [AA], combined androgen blockade [CAB]) or had orchiectomy (OT) between 1st July, 2010, and the 31st December, 2011, and followed them up to 31st December, 2013. The main analysis followed an 'on-treatment' approach that censored all patients at the time of first therapeutic modification; it used Cox regression analysis to estimate hazard ratios (HRs) for hospitalisations for ischaemic events (myocardial infarction or ischaemic stroke, whichever came first), adjusted on age, baseline co-morbidities and taking into account death as a competing risk. RESULTS: Among the 35,118 new ADT users, 71% received GnRH agonist (reference group), 12% CAB, 13% AA, 3.6% GnRH antagonist and 0.6% had OT. CAB was associated with an increased risk (adjusted HR [95% confidence interval {CI}], 1.6 [1.3-2.0]) and AA with a decreased risk (adjusted HR [95% CI], 0.6 [0.4-0.9]) of ischaemic events when compared to GnRH agonist. No significant association was found with GnRH antagonist (adjusted HR [95% CI], 1.2 (0.7-2.1)). CONCLUSION: CV risk appeared different across ADT modalities. The probability of a clinically meaningful difference when comparing GnRH antagonists to agonists appears rather low. In a context where better overall and cancer specific survival without worsening quality of life is a challenge for clinicians, a potential heterogeneity in CV morbidity becomes crucial when choosing an ADT.
引用
- Scailteux LM, Vincendeau S, Balusson F, et al. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. Eur J Cancer. 2017. PMID: 28390298. doi:10.1016/j.ejca.2017.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。